Publications and Social Media

Review of m6A and A-to-I modifications in cardiovascular diseases published in Molecular Therapy Nucleic Acids.

Full citation: Sikorski V, Vento A, Kankuri E; IHD-EPITRAN Consortium. Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases. Mol Ther Nucleic Acids. 2022 Jul 20;29:426-461. doi: 10.1016/j.omtn.2022.07.018. PMID: ; PMCID: PMC9366019.

IHD-EPITRAN study outline and aims. MD Vilbert Sikorski presented the IHD-EPITRAN study outline and aims at the as an ePOSTER on 13.11.2021. Click or .

Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives. Study protocol published in International Journal of Molecular Sciences.

Full citation: Sikorski V, Karjalainen P, Blokhina D, Oksaharju K, Khan J, Katayama S, Rajala H, Suihko S, Tuohinen S, Teittinen K, Nummi A, Nykänen A, Eskin A, Stark C, Biancari F, Kiss J, Simpanen J, Ropponen J, Lemström K, Savinainen K, Lalowski M, Kaarne M, Jormalainen M, Elomaa O, Koivisto P, Raivio P, Bäckström P, Dahlbacka S, Syrjälä S, Vainikka T, Vähäsilta T, Tuncbag N, Karelson M, Mervaala E, Juvonen T, Laine M, Laurikka J, Vento A, Kankuri E. Epitranscriptomics of Ischemic Heart Disease-The IHD-EPITRAN Study Design and Objectives. Int J Mol Sci. 2021 Jun 21;22(12):6630. doi: 10.3390/ijms22126630. PMID: ; PMCID: PMC8235045.

ClinicalTrials.gov study registration. Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN)